Human recombinant tissue-plasminogen activator (Alteplase): Why not use the human dose for stroke studies in rats?

Journal of Cerebral Blood Flow and Metabolism

Volumn 30, Issue 5, 2010, Pages 900-903

  Haelewyn, Benoît ^a,b   Risso, Jean Jacques ^c   Abraini, Jacques H ^b  

^a NNOXe Pharmaceuticals Inc   (Canada)

^b UNIVERSITÉ DE CAEN   (France)

^c IRBA   (France)

Author keywords

Acute ischemic stroke; Animal models; RtPA; Thrombolysis

Indexed keywords

ALTEPLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN EDEMA; BRAIN INFARCTION; CONTROLLED STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION; STROKE; THROMBOEMBOLISM;

ANIMALS; CEREBROVASCULAR CIRCULATION; FIBRINOLYTIC AGENTS; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; REGIONAL BLOOD FLOW; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 77952009799     PISSN: 0271678X     EISSN: None     Source Type: Journal    
DOI: 10.1038/jcbfm.2010.33     Document Type: Article

References (15)

1. Christou I, Alexandrov AV, Burgin WS, Wojner AW, Felberg RA, Malkoff M, Grotta JC (2000) Timing of recanalization after tissue plasminogen activator therapy determined by transcranial doppler correlates with clinical recovery from ischemic stroke. Stroke 31:1812-6
2. David HN, Haelewyn B, Rouillon C, Lecoq M, Chazalviel L, Apiou G, Risso JJ, Lemaire M, Abraini JH (2008) Neuroprotective effects of xenon: a therapeutic window of opportunity in rats subjected to transient cerebral ischemia. FASEB J 22:1275-86
3. David HN, Haelewyn B, Risso JJ, Colloc'h N, Abraini JH (2010) Xenon is an inhibitor of tissue-plasminogen activator: adverse and beneficial effects in rat model of thrombo-embolic stroke. J Cereb Blood Flow Metab 30:718-28
4. David HN, Leveille F, Chazalviel L, MacKenzie ET, Buisson A, Lemaire M, Abraini JH (2003) Reduction of ischemic brain damage by nitrous oxide and xenon. J Cereb Blood Flow Metab 23:1168-73
5. Delgado-Mederos R, Rovira A, Alvarez-Sabín J, Ribó M, Munuera J, Rubiera M, Santamarina E, Maisterra O, Delgado P, Montaner J, Molina CA (2007) Speed of tPA-induced clot lysis predicts DWI lesion evolution in acute stroke. Stroke 38:955-60
6. Haelewyn B, Alix P, Maubert E, Abraini JH (2008) NMDA-induced striatal brain damage and time-dependence reliability of thionin staining in rats. J Neurosci Methods 168:479-82
7. Henninger N, Küppers-Tiedt L, Sicard KM, Günther A, Schneider D, Schwab S (2006) Neuroprotective effect of hyperbaric oxygen therapy monitored by MR-imaging after embolic stroke in rats. Exp Neurol 201:316-23
8. Homi HM, Yokoo N, Ma D, Warner DS, Franks NP, Maze M, Grocott HP (2003) The neuroprotective effect of xenon administration during transient middle cerebral artery occlusion in mice. Anesthesiology 99:876-81
9. Korninger C, Collen D (1981) Studies on the specific fibrinolytic effect of human extrinsic (tissuetype) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost 46:561-5
10. Lee JM, Zipfel GJ, Choi DW (1999) The changing landscape of ischaemic brain injury mechanisms. Nature 399: A7-14
11. Lijnen HR, Hoylaerts M, Collen D (1980) Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as histidine-rich glycoprotein. J Biol Chem 255:10214-22
12. Meyer JS, Rauch G (2000) Why emergency XeCT-CBF should become routine in acute ischemic stroke before thrombolytic therapy. Keio J Med 49 (Suppl 1) : A25-8
13. Merino JG, Latour LL, An L, Hsia AW, Kang DW, Warach S (2008) Reperfusion half-life: a novel pharmacodynamic measure of thrombolytic activity. Stroke 39:2148-50
14. Stroke Therapy Academic Industry Roundtable (STAIR) (1999) Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30:2752-8
15. Schiltz M, Fourme R, Broutin I, Prangé T (1995) The catalytic site of serine proteinases asa specific binding cavity for xenon. Structure 3:309-16